

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

OE19

RRID:CVCL_1622

Type: Cell Line

Proper Citation

RRID:CVCL_1622

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1622

Proper Citation: RRID:CVCL_1622

Description: Cell line OE19 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Esophageal adenocarcinoma

Defining Citation: [PMID:9010035](#), [PMID:15511476](#), [PMID:16364037](#), [PMID:20075370](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23795680](#), [PMID:24083764](#), [PMID:25070024](#), [PMID:25877200](#), [PMID:26512696](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:34466148](#), [PMID:35839778](#)

Comments: Characteristics: Contains a 100 fold amplification of ERBB2 (PubMed=15511476)., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OE19

Synonyms: OE-19, JROECL 19, JROECL19, OEC19

Cross References: CLO:CLO_0008238, EFO:EFO_0002308, CLDB:cl3761, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03471032, BioSample:SAMN10988362, cancercellines:CVCL_1622, Cell_Model_Passport:SIDM00479, ChEMBL-

Cells:CHEMBL3308462, ChEMBL-Targets:CHEMBL1075555, Cosmic:871232, Cosmic:910079, Cosmic:978854, Cosmic:997860, Cosmic:1175878, Cosmic:1599342, Cosmic:1618819, Cosmic:1995600, Cosmic-CLP:910079, DepMap:ACH-000679, DSMZ:ACC-700, DSMZCellDive:ACC-700, ECACC:96071721, EGA:EGAS00001000978, GDSC:910079, GEO:GSM827301, GEO:GSM887475, GEO:GSM888555, GEO:GSM1264050, GEO:GSM1264051, GEO:GSM1264052, GEO:GSM1264053, GEO:GSM1264054, GEO:GSM1264092, GEO:GSM1264093, GEO:GSM1264094, GEO:GSM1264095, GEO:GSM1264096, GEO:GSM1670302, GEO:GSM7701391, GEO:GSM7701392, IARC_TP53:21600, IGRhCellID:OE19, LiGeA:CCLE_923, LINCS_LDP:LCL-1796, PharmacODB:OE19_1194_2019, PRIDE:PXD030304, Progenetix:CVCL_1622, PubChem_Cell_line:CVCL_1622, Wikidata:Q54931862

ID: CVCL_1622

Record Creation Time: 20220427T221356+0000

Record Last Update: 20260913T005649+0000

Ratings and Alerts

No rating or validation information has been found for OE19.

No alerts have been found for OE19.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 124 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.

Mersich I, et al. (2026) Multi-omic integration identifies broad drug resistance mechanisms and strategies to therapeutically reprogram cancer cells. *iScience*, 29(1), 114293.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Krygier K, et al. (2026) A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour-targeting function. *British journal of pharmacology*.

Gaspar M, et al. (2025) An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. *Journal for immunotherapy of cancer*, 13(8).

- Loong J, et al. (2025) Retroelement co-option disrupts the cancer transcriptional programme. *Genome medicine*, 17(1), 48.
- Plowman T, et al. (2025) Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses. *Science immunology*, 10(109), eadr1105.
- Stamati I, et al. (2025) Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs. *Molecular cancer therapeutics*, 24(9), 1295.
- Yang BH, et al. (2025) iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors. *Cell reports. Medicine*, 6(7), 102195.
- Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. *Cell stem cell*, 32(7), 1087.
- García-Castillo J, et al. (2025) MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NF κ B axis. *Molecular oncology*, 19(11), 3305.
- van der Zalm AP, et al. (2024) The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma. *Communications medicine*, 4(1), 89.
- Bozzarelli I, et al. (2024) miRNA-221 and miRNA-483-3p Dysregulation in Esophageal Adenocarcinoma. *Cancers*, 16(3).
- Ballout F, et al. (2024) Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(10), 2193.
- Amissah OB, et al. (2024) NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. *Cancer cell international*, 24(1), 64.
- Liu D, et al. (2024) Predictive biomarkers for response to TGF- β inhibition in resensitizing chemo(radiated) esophageal adenocarcinoma. *Pharmacological research*, 207, 107315.
- Castagnoli L, et al. (2023) Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. *Cellular oncology (Dordrecht)*, 46(3), 661.
- Zhong C, et al. (2023) Refined expression quantitative trait locus analysis on adenocarcinoma at the gastroesophageal junction reveals susceptibility and prognostic markers. *Frontiers in genetics*, 14, 1180500.
- Diluvio G, et al. (2023) A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase. *Molecular therapy oncolytics*, 28, 307.
- Li S, et al. (2023) Issues with RNF43 antibodies to reliably detect intracellular location. *PloS one*, 18(4), e0283894.